Epigallocatechin-3-gallate potently inhibits the in vitro activity of hydroxy-3-methyl-glutaryl-CoA reductase
- PMID: 21357570
- PMCID: PMC3073461
- DOI: 10.1194/jlr.M011817
Epigallocatechin-3-gallate potently inhibits the in vitro activity of hydroxy-3-methyl-glutaryl-CoA reductase
Abstract
Hydroxy-3-methyl-glutaryl-CoA reductase (HMGR) is the rate-controlling enzyme of cholesterol synthesis, and owing to its biological and pharmacological relevance, researchers have investigated several compounds capable of modulating its activity with the hope of developing new hypocholesterolemic drugs. In particular, polyphenol-rich extracts were extensively tested for their cholesterol-lowering effect as alternatives, or adjuvants, to the conventional statin therapies, but a full understanding of the mechanism of their action has yet to be reached. Our work reports on a detailed kinetic and equilibrium study on the modulation of HMGR by the most-abundant catechin in green tea, epigallocatechin-3-gallate (EGCG). Using a concerted approach involving spectrophotometric, optical biosensor, and chromatographic analyses, molecular docking, and site-directed mutagenesis on the cofactor site of HMGR, we have demonstrated that EGCG potently inhibits the in vitro activity of HMGR (K(i) in the nanomolar range) by competitively binding to the cofactor site of the reductase. Finally, we evaluated the effect of combined EGCG-statin administration.
Figures







Similar articles
-
Insight into the mechanism of polyphenols on the activity of HMGR by molecular docking.Drug Des Devel Ther. 2015 Aug 28;9:4943-51. doi: 10.2147/DDDT.S86705. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26357462 Free PMC article.
-
Cloning, Purification, and Characterization of the Catalytic C-Terminal Domain of the Human 3-Hydroxy-3-methyl glutaryl-CoA Reductase: An Effective, Fast, and Easy Method for Testing Hypocholesterolemic Compounds.Mol Biotechnol. 2020 Feb;62(2):119-131. doi: 10.1007/s12033-019-00230-1. Mol Biotechnol. 2020. PMID: 31758489
-
Recombinant 3-Hydroxy 3-Methyl Glutaryl-CoA Reductase from Candida glabrata (Rec-CgHMGR) Obtained by Heterologous Expression, as a Novel Therapeutic Target Model for Testing Synthetic Drugs.Appl Biochem Biotechnol. 2017 Aug;182(4):1478-1490. doi: 10.1007/s12010-017-2412-9. Epub 2017 Jan 30. Appl Biochem Biotechnol. 2017. PMID: 28138930
-
Review of synthesis, biological assay, and QSAR studies of HMGR inhibitors.Curr Top Med Chem. 2012;12(8):895-919. doi: 10.2174/156802612800166729. Curr Top Med Chem. 2012. PMID: 22352916 Review.
-
Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase.Am Heart J. 2002 Dec;144(6 Suppl):S27-32. doi: 10.1067/mhj.2002.130300. Am Heart J. 2002. PMID: 12486413 Review.
Cited by
-
Effect of 2-month controlled green tea intervention on lipoprotein cholesterol, glucose, and hormone levels in healthy postmenopausal women.Cancer Prev Res (Phila). 2012 Mar;5(3):393-402. doi: 10.1158/1940-6207.CAPR-11-0407. Epub 2012 Jan 13. Cancer Prev Res (Phila). 2012. PMID: 22246619 Free PMC article. Clinical Trial.
-
The associations between dietary flavonoid intake and hyperlipidemia: data from the national health and nutrition examination survey 2007-2010 and 2017-2018.Front Nutr. 2024 May 31;11:1374970. doi: 10.3389/fnut.2024.1374970. eCollection 2024. Front Nutr. 2024. PMID: 38883860 Free PMC article.
-
Anti-obesogenic and antidiabetic effects of plants and mushrooms.Nat Rev Endocrinol. 2017 Mar;13(3):149-160. doi: 10.1038/nrendo.2016.142. Epub 2016 Sep 16. Nat Rev Endocrinol. 2017. PMID: 27636731 Review.
-
Potential dual inhibitors of PCSK-9 and HMG-R from natural sources in cardiovascular risk management.EXCLI J. 2022 Jan 5;21:47-76. doi: 10.17179/excli2021-4453. eCollection 2022. EXCLI J. 2022. PMID: 35221836 Free PMC article. Review.
-
The effect of green tea (Camellia sinensis) on lipid profiles and renal function in people with type 2 diabetes and nephropathy: a randomized controlled clinical trial.Front Nutr. 2023 Dec 14;10:1253275. doi: 10.3389/fnut.2023.1253275. eCollection 2023. Front Nutr. 2023. PMID: 38162524 Free PMC article.
References
-
- Berry J. D., Liu K., Folsom A. R., Lewis C. E., Carr J. J., Polak J. F., Shea S., Sidney S., O'Leary D. H., Chan C., et al. 2009. Prevalence and progression of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated risk for cardiovascular disease: the coronary artery risk development in young adults study and multi-ethnic study of atherosclerosis. Circulation. 119: 382–389. - PMC - PubMed
-
- Steinberger J., Daniels S. R., Eckel R. H., Hayman L., Lustig R. H., McCrindle B., Mietus-Snyder M. L. 2009. Progress and challenges in metabolic syndrome in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism. Circulation. 119: 628–647. - PubMed
-
- Brown M. S., Goldstein J. L. 1980. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J. Lipid Res. 21: 505–517. - PubMed
-
- Edwards P. A., Lemongello D., Kane J., Shechter I., Fogelman A. M. 1980. Properties of purified rat hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase and regulation of enzyme activity. J. Biol. Chem. 255: 3715–3725. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases